you are here:

Shasun Pharmaceuticals Ltd.

BSE: 524552 | NSE: SHASUNPHAR | Series: NA | ISIN: INE317A01028 | SECTOR: Pharmaceuticals

BSE Live

Nov 17, 16:00
428.85 0.00 (0.00%)
No Data Available
  • Prev. Close


  • Open Price


  • Bid Price (Qty.)

    428.85 (3881)

  • Offer Price (Qty.)

    431.00 (1)

Shasun Pharmaceuticals is not traded on BSE in the last 30 days

NSE Live

Nov 17, 15:57
428.55 0.00 (0.00%)
No Data Available
  • Prev. Close


  • Open Price


  • Bid Price (Qty.)

    428.55 (4656)

  • Offer Price (Qty.)

    0.00 (0)

Shasun Pharmaceuticals is not traded on NSE in the last 30 days
Company History - Shasun Pharmaceuticals
 1976 - The Company was incorporated under the Companies Act, 1956 on
        19th April, as a Private Limited Company as Shasun Chemicals
        (Madras) Pvt. Ltd., and was converted into a Public Limited
        Company on 21st March 1992.
 1993 - The name of the Company was changed to Shasun Chemicals and
        Ltd., on 25th October, in terms of resolution passed under
        Section 21 of the Companies Act.  Fresh Certificate of
        Incorporation was obtained on 26th November.
 1994 - The Company recently received the prestigious `Trishul' award
        from CHEMEXCIL for exports during 1990-91.
      - The Company's maiden public issue of 15,10,000 equity shares
        (out of which 1,00,000 shares were reserved for This
        Credit and Investment Corporation of India Limited and 40,000
        shares for employees).
 1995 - The Company is embarking on a major expansion during the
        year for increasing the capacity of Ibuprofen & Ranitidine
        for the manufacture of two new drugs.
      - The Company has signed a technical collaboration and
        agreement with Nagase & Co., Japan, for the manufacture of S-
        Ibuprofen, a high value drug.
      - The company has commissioned wind mills for generation of
        The total installed capacity is 1 MW which will effect
        substantial savings in energy costs.
      - The company has set up a subsidiary - Shasun, Inc., at
        USA, in June, for marketing its products.
 1996 - The Company has been awarded the Certificate of Merit for 
        outstanding export performance for 1993-94 by CHEMEXCIL.
      - The Company has obtained the prestigious ISO 9002
        from Bureau Veritas Quality International, Switzerland, on
        26th September.
 1997 - The Company has signed a technology transfer agreement with
        Chirotech, U.K. for the manufacture of 5-Naproxen, an
        antinflammatory drug.  Chirotech is the technology marketing
        of Chiroscience, a company engaged in Research & Development
        chiral molecules.
      - Shasun USA Inc. has established itself as a full fledged
        marketing arm of the Company for the North American
      - The Company allotted 14.5% - 5,00,000 Redeemable Preference
        Shares of Rs. 100 each to Industrial Development Bank of India
        private placement basis, to augment long term working capital
      - The company has a technical collaboration with Nagase of
        Japan which will give an access to S. Ketoprofen, SPBA and   
        D-Naproxen by a new chiral auxilliary.
 1998 - Shasun Chemicals is a Madras-based company engaged in the
        manufacture of Ibuprofen, Ranitidine and intermediaries. 
 1999 - The company has signed technology transfer agreement with
        Tech of UK for the manufacture of S-Naproxen, an inflammatory
        drug through the bio-technology route.
      - The company had entered into a technological tie-up with
        Genpharm for process know-how, for the production of
        Form I.
      - The company has entered into an agreement with a Canadian
        formulation company for supplying Ranitidine.
      - The company is set to increase the capacity of its Cuddalore
        plant from 22 tonnes to 45 tonnes per month.
      - The agreement, which is officially termed a `joint venture'
        company officials, is the first of its kind Austin has with
        company around the world.
      - The Company has an agreement with Austin Chemical Company of
        the US under which Austin would liasie with drug MNCs and get
        Shasun contracts for development of molecules.
 2000 - The Company manufacturer of bulk drugs and their
               is all set to enter the formulations segment with its
               tie-up with the US-based Eastman Chemical Company.
            - The Company signing the letter of intent under which
               Chemical Company, USA licence its technology for
               hydorxyprpylecellulose phthalate, pharmaceutical
 excipient to the
             - The Company has been given the Visveswarayya Industrial
 Award bys
                the All India Manufacturers Organisation.
             - The Company has bagged the merit trophy for quality
 excellence from the
                Indian Drug Manufacturers Association.
 -Board approves for hiving of its manufacturing unit , manufacturing
 ibuprofen into a separate joint venture company with a foreign drug
 -Forms an alliance with Eastman Chemical Co. Ltd of US to license the
 latters technology for the manufacture of acyrlic emulsion.
 -Fire accidents in one of the packing sections of Cuddalore factory.
 -Obtaines US FDA approval for its three bulk active pharmaceutical
 -Enters into alliance with Suven Pharmaceuticals Ltd and Innovasynth
 Technologies Ltd for drug discovery.
 -Enters into a pact with Eli Lilly and Co. for manufacture of API
 -Brings down the average effective cost of its term loans to 5% from
 the level of 10% in last year.
 -Board approves for the issue and allotment of 9,40,000 shares on a
 preferential basis.
 -US-based Genome Technologies enters into a bioinformatics deal with
 the company on the heels of cost advantage offered by India.
 -GMO Emerging Market Fund acquires 9,10,000 shares amounting to 9.96%
 of total paid up capital of the company.
 -Dr. Ashish Mukherjee has been appointed as the Chief Scientific
 Officer (CSO).
 -Chennai-based bulk drug maker Shasun Chemicals on June 15 announced
 its strategic alliance with Eastman Chemicals of the US for the
 development and manufacture of performance chemicals
 -Shasun Chemicals signs mfg & supply agreement with Codexis, USA
 -Shasun Chemicals enters into an agreement with Alpharma.
 -Company has splits its Face value of Shares from Rs 10 to Rs 2
 - Shasun Chemicals signs technology licensing Agreement with
 - Shasun Chemicals technology has announced that it has entered into
 a non-exclusive licensing agreement with Merck & Co., Inc.
 - Shasun Chemicals Board recommends dividend of 50% (Rs 1 per share)
 on the equity share of Rs 2/-  each.
 - Shasun Chemicals and Drugs Ltd appointed Mr. Dinesh Bhutda as
 Company Secretary w.e.f. April 01, 2009 as decided in the Board
 Meeting held on January 22, 2009.
 - The Company has entered into the rapidly growing filed of
 Nanotechno by entering into collaboration with Nanoparticle Biochem
 -Company has changed its name from Shasun Chemicals & Drugs Ltd. to
 Shasun Pharmaceuticals Ltd.       
 --Registered Office of the Company has been shifted to 'Batra Centre'
 28, Sardar Patel Road, 3rd and 4th floor, Guindy, Chennai 600032,
 Tamil Nadu,                                         
 - Shasun Chemicals and Drugs Ltd Appointed M/s. B. S. R. & Co.
 Chartered Accountant as statutory auditors of the Company
 - Shasun Pharmaceuticals Ltd turnover crosses Rs. 1000 crores as it
 celebrates its 35 years of service to the pharmaceutical industry.
 - Sun Pharma won the patent battle against Novo-Nordisk in the US
 Supreme Court over its generic drug ‘Prandin&rsquo.
 -Shasun Pharmaceuticals rallies over 12% on Sundaram Mutual Fund
 stake buy.
 -Shasun Pharma - Successful completion of MHRA EU inspection.
 -Sequent Scientific Ltd & Shasun Pharmaceuticals Ltd announce Joint
 Venture to Create Leading Animal Health Company.
 -Shasun Pharmaceuticals Ltd and Debiopharm Group enter into licensing
 agreement for the manufacturing and commercialization of Huperzine-A.
 -Shasun Signs Licence With MPP to Produce Low-Cost HIV Medicines.
 -Shasun Pharma Successful completion of US FDA and Mexican COFEPRIS
 -Shasun Pharma Updates Joint venture agreement with Sequent
 Scientific Ltd.
 -Shasun Pharma Acquisition of Global rights of Ibuprofen 12 Hr
 Extended Release OTC & Nuprin brand.
 -Shasun & Strides Arcolab Ltd  (Strides) have approved a Scheme of
 Amalgamation between the two companies.